Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Animal Models in Neurology: Drawbacks and Opportunities.
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Food and Drug Administration briefing document for ofatumumab
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.

Pages